Genetic diversity and the heterogeneous nature of cardiac fibroblasts (CFbs) have hindered characterization of the molecular mechanisms that regulate cardiac fibrosis. The Hybrid Mouse Diversity Panel offers a valuable tool to examine genetically diverse cardiac fibroblasts and their role in fibrosis.
A
cute myocardial injury or elevated pressure in the heart results in a multitude of cardiac pathologies, particularly cardiac fibrosis. It has been reported that such injury leads to activation and proliferation of cardiac fibroblasts (CFbs), some of which deposit excessive extracellular matrix components that compromise myocardial structure and function.
1,2 Despite the significant role that CFbs play in injury response, characterization of this cell type has been challenging due to their heterogeneous nature and lack of fibroblast-specific markers. 2, 3 Furthermore, detailed knowledge of the molecular mechanisms that regulate their specific contributions to scar development is lacking.
The Hybrid Mouse Diversity Panel (HMDP) is a collection of >100 genotyped inbred strains of mice that allow for identification of genetic factors that contribute to various common disease traits. 4 In a comprehensive study by Rau et al, 5 mice within the HMDP were phenotypically characterized after chronic treatment with isoproterenol (ISO), a β-adrenergic agonist. Excessive stimulation of β-adrenergic receptors in the heart has been linked to increased CFb proliferation and collagen synthesis. 5 Chronic treatment of the HMDP with ISO resulted in a wide range of severity in cardiac hypertrophy and associated fibrosis across the different strains. These findings support the hypothesis that genetic variation influences the development and progression of cardiac dysfunction and pathological fibrosis. However, these studies evaluated changes at the cardiac tissue level and did not delineate the roles of specific cell types to each strain's respective phenotype.
In the present study, we utilized 3 HMDP strains with varying responses to ISO treatment to investigate the mechanisms by which their respective CFbs may regulate the process of cardiac fibrosis. We demonstrated that CFbs respond to ISO in a strain-specific manner both in vitro and in vivo. It is notable that CFbs from all 3 strains exhibited significant differences in levels of activation in response to ISO but had similar rates of proliferation. In addition, we performed RNA sequencing and identified various molecular pathways that were differentially enriched across the 3 strains in response to ISO. RNA sequencing further unveiled genes that were commonly upregulated in CFbs from all 3 strains. Within these genes, we validated Ltbp2 as a potential marker of fibrosis that can be applied to a genetically diverse population. Overall, our findings contribute to the understanding of cardiac fibroblast function in the context of ISO-induced cardiac fibrosis and further highlight the importance of genetic variation in complex diseases and cellular functions.
METHODS
The data, analytic methods, and study materials will be made available to other researchers for purposes of reproducing the results or replicating the procedure. The authors declare that all supporting data are available within the article and its online-only Data Supplement files. The transcriptomics data are available under the GEO accession ID GSE109376.
Mice
Adult female C57BL/6J, C3H/HeJ, and KK/HlJ mice (8-10 weeks) were obtained from Jackson Laboratory (Bar Harbor, ME). All procedures were carried out with the approval of the University of California, Los Angeles (UCLA) Animal Research Committee or the Institutional Animal Care. Two operators blinded to the experimental designs performed all animal surgeries and in vivo analyses.
ISO Treatment
ISO treatment was performed by implantation of Alzet osmotic pumps (Cupertino, CA) in C57BL/6J, C3H/HeJ, and KK/HlJ mice (n=20). Pumps were filled with ISO (Sigma, CA; 30 mg/kg body weight/per day) and implanted in the abdominal cavity under anesthesia with isoflurane. Mice were treated pre-and postoperatively with Sulfamethoxazole and Trimethoprim oral suspension (Hi-Tech Pharmacal, Amityville, NY). Mice in control groups were implanted with pumps filled with saline. Mice were euthanized and hearts were harvested 14 or 21 days postimplantation for further analysis (n=52).
Clinical Perspective
What Is New?
• This study uses a novel multiple-strain approach to characterize the contributions of cardiac fibroblasts to the formation of isoproterenol-induced cardiac fibrosis.
• While cardiac fibroblast activation levels correlated with the extent of fibrosis, proliferation was found to be similarly increased across all strains, suggesting that these 2 responses are not mutually inclusive.
• Ltbp2 was identified as a common gene that is upregulated within all strains after treatment with isoproterenol and LTBP2 was shown to localize in areas of fibrosis in the myocardium of patients with heart failure, suggestive of its potential as a biomarker for fibrosis.
What Are the Clinical Implications?
• Understanding the responses of genetically diverse cardiac fibroblasts to injury will allow for the development of efficacious therapies for treating cardiac fibrosis.
• The results of this study suggest that levels of cardiac fibroblast proliferation may not be an indicative measure of the extent of cardiac fibrosis.
• The specificity of LTBP2 expression in the fibrotic regions of the myocardium suggests that it may be a potential target for reducing levels of cardiac fibrosis.
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Primary Cardiac Fibroblast Culture and Characterization
Cardiac fibroblast isolation was prepared as described in the Methods online-only Data Supplement (Table I in . Media were changed 24 hours after the primary culture, followed by changes every 48 hours. Cells were passaged on 80% confluency. After the first passage, cells were washed and cultured in serum-free culture medium supplemented with 0.5 mg/mL insulin and 0.5 mg/mL transferrin. At confluence, cells were treated with 100 µm/L ISO (Sigma) or 50 ng/mL transforming growth factor β (TGFβ; Cell Signaling). After 72 hours, cells were washed, fixed in 4% paraformaldehyde, and stained for analysis. Cell counts were performed on ImageJ using the 'Cell Counter' plug-in by 2 people blind to the conditions.
Inhibition of In Vitro Cell Proliferation
Cells were isolated, expanded, and passaged on 80% confluency with serum-free culture media (2.5×10 4 cells per well). Before treatment with ISO, cells were treated with mitomycin-C (10μg/mL; Acros Organics) for 2 hours or irradiated for 2 minutes at 3 Gy.
RNA Sequencing
Thy1
+ HE − CFbs were isolated from saline and ISO-treated hearts 14 or 21 days after pump implantation (n=2 per strain/condition), and then sorted directly into TRIzol® LS Reagent (Ambion). Total RNA was extracted using the RNeasy miniElute Cleanup Kit (Qiagen), according to manufacturer's instructions. Complementary DNA (cDNA) libraries were generated using reagents provided in the KAPA mRNA Hyperprep kit. The amplified cDNA library was sequenced on an Illumina HiSeq 3000 according to manufacturer's instructions. Libraries were sequenced using 50 single-end read protocol, which yielded ≈20 million raw reads per sample. Read quality was assessed using FastQC, and reads were subsequently trimmed 5 bp from the start of the reads up and 2 bp from the end of the reads. Alignment to the mm10 mouse genome were performed using STAR v2.5.3a with -twopassMode Basic option. Gene counts were generated using -quantMode GeneCounts option. Raw gene counts were transformed to counts per million and log2-counts per million data matrix and further normalized by trimmed mean of M-values method in the edgeR Bioconductor package. Genes with counts per million <1 across all samples were excluded from further analysis. To determine differentially expressed genes, the voom method of limma was applied, accommodating the mean-variance in the linear model using precision weight, and significant gene set was selected with nominal P value <0.05 threshold. Global functional analyses, network analyses, and canonical pathway analyses were performed using Ingenuity Pathway Analysis (Ingenuity® Systems, www.ingenuity.com).
Statistical Analysis
Statistical testing was performed with GraphPad Prism 6. Results are presented as mean±SEM and were analyzed using 1-way ANOVA, 2-way ANOVA, or Student t test (significance was assigned for P<0.05). Multiple comparisons were considered by Tukey's multiple comparison test, the Sidak method, or the Holm-Sidak method.
RESULTS
Pathological Analysis of ISO-Induced Cardiac Function and Fibrosis in Selected Mouse Strains
The entire HMDP was characterized at baseline and in response to ISO treatment to determine the extent of cardiac fibrosis ( Figure 1A ). The survey revealed significant variations in cardiac pathophysiology and fibrosis under baseline conditions and in response to ISO administration. 5, 6 Based on this considerable variability, we selected 3 representative strains that exhibited distinct pathological phenotypes: C57BL/6J, C3H/HeJ, and KK/HIJ, showing minimal, moderate, and substantial myocardial fibrosis after ISO injury, respectively. Adult female mice (8-10 weeks, 20-28 g) from each strain were intraperitoneally implanted with an Alzet micro-osmotic pump containing saline or ISO. Mice from all strains were of similar size ( Figure IA in the online-only Data Supplement) and body weight (data not shown). Throughout the course of treatment, the mice did not display adverse physical symptoms in response to ISO. After 21 days of treatment, animals were euthanized and hearts were harvested for analysis. Masson's trichrome staining demonstrated minimal to no visible fibrotic areas in all mice treated with saline ( Figure 1B ). After ISO treatment, both C3H/ HeJ and KK/HlJ hearts exhibited clear fibrotic areas (blue), whereas C57BL/6J hearts had minimal amounts of fibrosis. Consistent with the histological observations, quantitative analysis of the fibrotic areas showed significant differences across the selected strains, with KK/HIJ hearts consistently exhibiting the greatest area of fibrosis in response to ISO (C57BL/6J: saline=0.1±0.1% ISO=1.2±0.1%, C3H/HeJ: saline=0.3±0.1% ISO=2.4±0.4%, KK/HlJ: saline=0.3±0.1% ISO=6.4±0.7%; Figure 1C ). In addition, ISO treatment caused observable increases in heart size ( Figure IB in the online-only Data Supplement) and heart weight/tibia length ratios ( Figure IC in the online-only Data Supplement) in both KK/HIJ and C3H/HeJ strains, whereas C57BL/6J mice showed minimal signs of cardiac hypertrophy.
Functional echocardiography analysis demonstrated increased left ventricle end-diastolic dimension and end-systolic dimension in the C3H/HeJ and KK/ HIJ strains 21 days after ISO treatment ( Figure ID These results confirm that chronic β-adrenergic stimulation in different mouse strains leads to varying severity of cardiac fibrosis. These phenotypic differences were used to further characterize the contributions of CFbs to ISO-induced fibrosis.
In Vitro Characterization of Strain-Specific Cardiac Fibroblasts in Response to ISO
Based on the varying levels of fibrosis exhibited by the 3 selected strains, we focused on characterizing strainspecific CFbs and their potential role in generating the observed patterns of cardiac fibrosis. Initially, CFbs from each strain were isolated and cultured as described in the Methods in the online-only Data Supplement.
2 Although our isolation protocol does not purify the entire CFb population, it ensures that the same population of cells will be compared across the 3 strains. Phase contrast images and immunocytochemistry confirmed that CFbs from all strains exhibit similar mesenchymal morphology ( Figure IIA in the online-only Data Supplement) and express fibroblast markers collagen 1 (Col1) and platelet-derived growth factor receptor alpha (Figure IIB and IIC in the online-only Data Supplement). We then sought to determine whether these fibroblasts exhibited similar patterns of activation and proliferation in culture. CFbs were stained for the expression of α-smooth muscle actin (αSMA), a marker associated with activated fibroblasts, 7 and phospho-Histone H3 (pHH3) 8 for proliferation analysis. We observed very low expres- 
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sion of αSMA within Col1 + CFbs from all strains ( Figure  IID and IIE in the online-only Data Supplement), indicating that these cells do not become activated without stimuli, and observed similar rates of proliferation (%pHH3 + nuclei) at the basal level ( Figure IIF and IIG in the online-only Data Supplement).
We next examined whether strain-specific CFbs may have differential responses to ISO in vitro. CFbs from each strain were isolated, expanded, and passaged before being treated with culture media containing ISO (Figure 2A ). Cells were then fixed and characterized by phase contrast microscopy ( Figure 2B) Figure 2E and 2F). CFbs isolated from mice pretreated with implanted ISO osmotic pumps ( Figure IIIA in the online-only Data Supplement) did not exhibit significant changes in activation or proliferation in response to additional in vitro ISO treatment ( Figure IIIB and IIIC in the online-only Data Supplement). This may be attributed to an already stimulated state of cells before culture, resulting in minimal response to ISO in vitro. 9 We additionally treated CFbs in vitro with TGFβ, a profibrotic cytokine, for 72 hours ( Figure IVA in the onlineonly Data Supplement). 10 The Together, these data suggest that cultured CFbs respond to ISO in a strain-specific manner. Although ISO treatment resulted in differing levels of activation in cultured CFbs, their levels of proliferation were similar.
Cardiac Fibroblasts Demonstrate StrainSpecific Responses to ISO Treatment In Vivo
Whereas other studies have viewed fibroblast activation and proliferation to be interdependent responses ORIGINAL RESEARCH ARTICLE to stimulation, our in vitro results suggest otherwise. To determine whether a similar behavior is observed in vivo, we investigated CFb activation and proliferation after ISO stimulation in the three selected strains.
First, we observed the presence of activated fibroblasts in C57BL/6J, C3H/HeJ, and KK/HlJ mice in response to ISO treatment. Immunohistochemistry was used to observe colocalization of Col1 with αSMA or periostin for the identification of activated CFbs. 11, 12 In all saline-treated groups, Col1 staining was mainly present around larger vessels and colocalization with αSMA was exceedingly rare ( Figure 3A Figure 3B ). Immunohistochemistry for periostin also confirmed the differential levels of acti- 
ORIGINAL RESEARCH ARTICLE
vated CFbs observed across the 3 strains ( Figure VB in the online-only Data Supplement). Consistent with our in vitro results, the levels of CFb activation corresponded with the amount of fibrosis seen within each strain. Next, we sought to assess the proliferative behavior of CFbs in vivo after ISO injury. Mice were injected with bromodeoxyuridine (BrdU) at the time of microosmotic pump implantation for saline/ISO and exposed to BrdU diluted in drinking water throughout the 21 days of treatment ( Figure 3C) . Immunohistochemistry of the saline-treated hearts demonstrated low levels of BrdU + proliferating CFbs throughout the myocardium. However, with ISO treatment, we observed a significantly higher number of BrdU + cells throughout the perivascular and interstitial Col1 + regions in all 3 strains ( Figure 3D ). Flow cytometry demonstrated similar percentages of BrdU + CFbs in the control groups for all 3 strains. The proportion of BrdU + CFbs significantly increased to a similar amount after ISO treatment in all 3 strains (C57BL/6J: saline=5.8±1.5% ISO=20.9±0.6%, C3H/HeJ: saline=7.1±0.8% ISO=32.7±5.3%, KK/HlJ: saline=6.2±0.8% ISO=23.4±1.4%; Figure 3E These results demonstrate that although the extent of cardiac fibrosis directly correlated with the number of activated CFbs, a similar pattern of CFb proliferation was observed in all 3 strains after ISO treatment.
Inhibition of Cardiac Fibroblast Proliferation In Vitro Does Not Affect Their Activation Levels
Our results suggest that CFb proliferation and activation may be distinct responses to ISO treatment with different phenotypic presentation depending on genetic background. To confirm this, we sought to inhibit CFb proliferation in vitro and determine whether it would affect the activation of these cells.
CFbs from each strain were isolated, cultured, and subjected to 1 of 3 conditions: (1) culture in normal media, (2) treatment with mitomycin-C (mito-C) for 2 hours, or (3) irradiation (IR) for 2 minutes. We chose treatment with mito-C or irradiation as 2 independent methods to inhibit CFb proliferation. 13 We then exposed the cells to ISO and conducted immunocytochemistry for pHH3 and αSMA ( Figure 4A ). In all three strains, the percentages of pHH3 + nuclei were significantly reduced after mito-C and IR treatment (C57BL/6J: Control=17.38±6.1% Mito-C=0.5±0.3% IR=3.5±1.3%, C3H/HeJ: Control=11.69±1.5% Mito-C=2.2±0.9% IR=3.7±1.6%, KK/HlJ: Control=14.8±0.5% Mito-C=0.3±0.3% IR=2.7±1.8%; Figure 4B ). However, we did not observe significant differences in the percentage of CFbs that expressed markers for CFb activation such as αSMA (C57BL/6J: Control=0.2±0.1% Mito-C=0.1±0.1% IR=1.5±0.7%, C3H/HeJ: Control=5.0±0.7% Mito-C=4.1±1.6% IR=2.5±0.8%, KK/HlJ: Control=18.5±8.5% Mito-C=13.11±2.06%, IR=8.1±0.7%; Figure 4C ). These results confirm that CFb proliferation and activation do not necessarily correlate with each other and may contribute to fibrosis in unique manners.
Strain-Specific Cardiac Fibroblasts Have Unique Transcriptional Profiles in Response to In Vivo ISO Treatment
The use of multiple genetic strains for transcriptome analysis allows for a comprehensive approach to determine potential genetic contributors of specific phenotypes. To further characterize CFbs within the 3 selected strains, we performed RNA sequencing on isolated CFbs from C57BL/6J, C3H/HeJ, and KK/HlJ mice that underwent saline or ISO treatment for 21 days. The effects of ISO on each strain's transcriptome was unique, as seen by the global heatmap of differential gene expression of all three strains, further justifying the need to study strain-specific phenotypes ( Figure 5A ). Based on the in vitro and in vivo results, we focused on genes mainly associated with fibrosis and proliferation. We observed that genes related to fibroblast activation and fibrosis were highly upregulated in KK/HIJ CFbs in response to ISO compared with C3H/HeJ and C57BL/6J CFbs (Figure 5B) . In contrast, we observed comparable expression levels of select cell cycle and proliferation genes across the 3 strains ( Figure 5C ).
Furthermore, we used Ingenuity Pathway Analysis to identify enriched pathways which may be involved in regulating such differences within each strain ( Figure 
Ltbp2 Is Upregulated in Response to Cardiac Fibrosis
Like genome-wide association studies, the HMDP facilitates identification of unique genes that may be associated with complex phenotypic traits. To account for diversity seen in heart failure pathologies, we sought to identify genes that can be associated with fibrosis regardless of genetic background. From the RNA sequencing data, we focused on genes that were upregulated within each strain in response to ISO. Several of these genes overlapped across 2 strains, but the majority of the genes were unique to each strain ( Figure 6A) . We focused on genes that were upregulated in all 3 strains in response to ISO and identified Ltbp2 to be of interest ( Figure 6B and Figure VIIIA in the online-only Data Supplement). Reverse transcription-qPCR (RT-qP-CR) for Ltbp2 within CFbs confirmed the trends seen within the RNA sequencing data (C57BL/6J: 2.0±0.5, C3H/HeJ: 3.6±0.7, KK/HlJ: 3.2±0.8; Figure 6C and Table II in the online-only Data Supplement).
To confirm the presence of LTBP2 protein in fibrosis, we conducted immunohistochemistry on cardiac sections from all 3 strains after ISO treatment. In salinetreated hearts, there was minimal expression of LTBP2 throughout the myocardium ( Figure 6D ). However, in 
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response to ISO, LTBP2 colocalized with DDR2, a marker for fibroblasts, and αSMA ( Figure 6D ). The expression of LTBP2 was specifically localized to the fibrotic regions, even in C57BL/6J hearts, where there was minimal fibrosis ( Figure 6D ). Because it is a secreted protein, we additionally sought to determine whether ISO treatment elevates LTBP2 levels in circulation. We found that LTBP2 levels were significantly increased in plasma of KK/HlJ mice, with increasing trends in C57BL/6J and C3H/HeJ mice, after ISO treatment ( Figure VIIIB in the online-only Data Supplement and Table III in the onlineonly Data Supplement).
To determine whether LTBP2 expression is also present in other models of fibrosis, we performed transverse aortic constriction surgery on the 3 mouse strains. 16 We observed cardiac hypertrophy and the presence of myocardial fibrosis in the 3 strains after transverse aortic constriction (data not shown). In C57BL/6J mice, RNA sequencing and RT-qPCR demonstrated significant increases in Ltbp2 expression in CFbs 7 days after transverse aortic constriction surgery compared with sham ( Figure VIIIC and VIIID in the online-only Data Supplement). In addition, immunohistochemistry showed that LTBP2 was preferentially localized in the fibrotic areas within the myocardium of mice that underwent transverse aortic constriction ( Figure 6D ). Last, we investigated whether LTBP2 is upregulated in human plasma with underlying heart failure. We found that average LTBP2 levels were mildly increased in patients with heart failure with reduced ejection frac- Table IV in the online-only Data Supplement). Furthermore, immunohistochemistry staining of human myocardial tissue from heart failure patients revealed LTBP2 expression to be significantly increased compared with expression in the healthy human myocardium ( Figure IXB in the online-only Data Supplement).
Taken together, our results suggest that the expression of LTBP2 may be indicative of the development of cardiac fibrosis, but its specific role in fibrosis requires further exploration.
DISCUSSION
Despite the functional significance of CFbs in cardiovascular disease, the specific contributions of these cells to cardiac fibrosis are not completely understood. Previous studies revealed a wide spectrum of cardiac pathology across various inbred strains of mice when subjected to chronic β-adrenergic stimulation by ISO. 5, 6 We hypothesized that characterizing fibroblasts of multiple strains with different severities of ISO-induced cardiac fibrosis would allow us to dissect the contributions of these cells to scar development. Our results show that fibroblast activation, not proliferation, correlates with the striking differences in fibrosis among the divergent strains. Moreover, comparisons of gene expression profiles across the strains revealed differences in underlying mechanistic pathways and led to the identification of a potential marker of fibrosis.
Whereas recent research has focused on how CFbs become activated and proliferate in response to injury, 17 the mechanisms by which these processes dictate scar development have yet to be elucidated. Before this study, CFb activation and proliferation were generally considered to be interconnected responses that contribute to fibrosis. 17, 18 Here, by comparing CFbs from 3 selected strains of the HMDP-C57BL/6J, C3H/HeJ, and KK/HlJ-we discovered that there is a direct correlation of CFb activation with the severity of fibrosis, while CFbs from all strains exhibited similar proliferative capacity in response to ISO. These results suggest that CFb proliferation may be an independent response from CFb activation and that levels of proliferation do not necessarily correlate with the extent of scar formation. It is possible that CFb proliferation is an indicator of CFb stimulation, but the functional roles of this phenomenon require further studies. Myocardial injury evokes multiple signaling pathways in cardiac fibroblasts that ultimately lead to the activation of genes that regulate cardiac fibrosis. 19 To delineate gene expression differences between CFbs from each select strain, we conducted RNA sequencing on sorted CFbs after saline and ISO treatment. After ISO treatment, CFbs from each strain responded with distinct changes in their gene expression profiles. Our results revealed many genes with small fold changes, and the analysis was conducted to be inclusive of these changes. We observed enrichment of fibroblast activation genes that paralleled the extent of fibrosis observed in each strain, while the upregulation of proliferation genes was comparable across all strains. Ingenuity Pathway Analysis identified the GP6 signaling pathway as exhibiting activation scores that corresponded with the levels of fibrosis seen across the 3 selected strains. GP6 is a collagen receptor abundantly expressed on platelets that activates a downstream signaling cascade promoting platelet aggregation and thrombus formation. 20 The role of this signaling pathway in fibroblasts has yet to be explored, but our results suggest that modulation of this signaling cascade may regulate the formation of fibrosis. Our RNA sequencing data also revealed that genetic differences may influence the timely progression of scar formation. In C57BL/6J mice, CFbs were not immune to ISO treatment, but rather exhibited a downregulation of profibrotic pathways between day 14 and day 21 of treatment. On the contrary, C3H/HeJ mice appeared to display a slow progression toward the formation of fibrosis, evidenced by the continuing changes in gene expression profiles between day 14 and day 21. Last, KK/HlJ mice, as the most sensitive strain, exhibited surprisingly few changes in canonical pathway activation between day 14 and day 21 of treatment, suggesting that CFbs may have already undergone transcriptional changes in response to ISO before the time of analysis. Ultimately, these findings raise questions regarding whether phenotypic or transcriptomic changes observed after cardiac injury within a single mouse strain can be applicable to other strains. It is important to interrogate these pathways to gain insight into mechanisms of CFb activation, explore how cardiac fibrosis is regulated, and perhaps design novel antifibrotic therapies.
Heart failure resulting from prolonged interstitial fibrosis is a highly heterogeneous disorder influenced by many environmental and genetic factors. Genomewide association studies allows for the identification of genetic variations on complex traits such as heart failure. 21 However, multiple large-scale genome-wide association studies have provided limited success in identifying genetic signals driving heart failure. 22 This is partly attributable to the paucity of quantitative phenotypic data as well as diverse environmental factors. Therefore, there have been challenges in developing treatments for heart failure and cardiac fibrosis that are applicable to a diverse population. The HMDP is a unique tool to mimic in mice the genetic variance and substantial diversity of heart failure development seen in humans. Whereas previous studies have sought to identify genetic markers uniquely associated with heart failure in a specific genetic background, we sought to investigate common markers that are associated with cardiac fibrosis in a panel of genetically diverse mouse strains. Our results revealed Ltbp2 to be upregulated in CFbs from all 3 strains and that the expression of LTBP2 was primarily localized in the fibrotic regions. LTBP2 is part of the Latent TGFβ1-Binding Protein family, which have been shown to participate in the regulation of TGFβ signaling and display high affinity binding sites for extracellular matrix proteins. However, whereas the functions of LTBP1, 23 LTBP3, 24 and LTBP4 25 in disease have been extensively characterized, the role of LTBP2 in cardiac injury is still unclear. Whether LTBP2 is merely a surrogate for cardiac fibrosis or is involved in its pathogenesis is not entirely known. Furthermore, the specificity of LTBP2 to cardiac fibrosis, and its potential role in the manifestation of other types of organ fibrosis, cannot be disregarded. However, our results in both mice and human heart failure patients support the possibility of LTBP2 being used as a marker for fibrosis that can be used across a genetically diverse population.
Our data demonstrates the importance of considering genetic backgrounds when conducting studies on CFbs that reflect changes in cardiac phenotype in response to injury. The comparisons conducted across multiple strains allowed for a unique approach in associating CFbs with a spectrum of ISO-induced fibrosis, rather than just the presence of fibrosis itself. This form of analysis allowed us to determine significant factors that directly correlate with the development of scar tissue, which may have not been recognized if the study was done within a single strain. This multiple-strain approach, when combined with molecular and cell-based characterizations, serves as an important tool for future work delineating the functions not only of CFbs, but also of a variety of cardiac cell types.
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